May 18, 2025, 01:04

SOSCLC – AECC: Small Cell Lung Cancer. From Biological Networks to Personalized Therapy

Directed by Drs. Luis Paz-Ares and Marcos Malumbres, this project is Spain’s first nationwide collaborative effort focused on small cell lung cancer (SCLC), one of the most aggressive and deadly forms of cancer. Backed by the Spanish Association Against Cancer (AECC), the SOSCLC consortium brings together over 300 researchers from across Spain, coordinated by Hospital 12 de Octubre and Vall d’Hebron Institute of Oncology (VHIO), and supported by international institutions and companies dedicated to lung cancer research.

SCLC typically spreads rapidly, has poor prognosis, and is often diagnosed at an advanced stage—with only 3% of such patients surviving beyond five years. While tobacco use remains the primary risk factor, other environmental and occupational factors remain underexplored.

The key objectives of SOSCLC include:

Studying the distribution and risk factors of SCLC in Spain
Investigating cellular alterations and immune evasion mechanisms to develop targeted therapies
Promoting patient involvement in research and increasing public awareness of the disease

This initiative reflects a powerful convergence of science, clinical care, and patient advocacy to transform the treatment landscape of SCLC in Spain.

AECC cancer risk factors cancer therapy Hospital 12 de Octubre immune evasion Luis Paz-Ares Lung cancer lung cancer treatment Marcos Malumbres oncology consortium oncology research Patient Advocacy personalized medicine Public Awareness SCLC small cell lung cancer SOSCLC Spain translational research Vall d’Hebron Institute of Oncology

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025